Prescribing information available here
Adverse event reporting information can be found at the bottom of this page
The majority of patients are satisfied with Easyhaler® and prefer it over their previous inhaler.1 Patient satisfaction with their inhaler is associated with high treatment adherence and better clinical outcomes.1–3
Bufomix Easyhaler Contraindications and Undesirable effects
Contraindications: Hypersensitivity to the active substances or lactose monohydrate (which contains small amounts of milk protein).
Undesirable effects:
Common (≥1/100 to < 1/10): Candida infections in the oropharynx, pneumonia (in COPD patients) headache, tremor, palpitations, mild irritation in the throat, coughing, dysphonia including hoarseness.
See SmPC for full list of adverse reactions
Date of preparation: October 2024 / EASYH-2726(1)
References
- Valero A, Ribó P, Maíz L, et al. Asthma patient satisfaction with different dry powder inhalers. Expert Rev Respir Med. 2019;13:133–138.
- Gálffy G, Mezei G, Nemeth G et al. Inhaler Competence and Patient Satisfaction with Easyhaler®: Results of Two Real-Life Multicentre Studies in Asthma and COPD. Drugs R D 2013 Sep;13(3):215–22.
- Plaza V, Giner J, Calle M, et al. Impact of patient satisfaction with his or her inhaler on adherence and asthma control. Allergy Asthma Proc 2018;39:437–444.
DATE OF PREPARATION: MAY 2023/EASYH-688(10)
FULL PRESCRIBING INFORMATION AVAILABLE HERE
For more information about Orion and Sustainability click here
| Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com |
